KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $136.0 million.

  • Jazz Pharmaceuticals' Net Cash Flow fell 8417.4% to $136.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$896.3 million, marking a year-over-year decrease of 20184.72%. This contributed to the annual value of $908.2 million for FY2024, which is 4562.16% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Net Cash Flow stood at $136.0 million, which was down 8417.4% from -$676.7 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Net Cash Flow high stood at $1.0 billion for Q1 2021, and its period low was -$1.2 billion during Q2 2021.
  • In the last 5 years, Jazz Pharmaceuticals' Net Cash Flow had a median value of $54.4 million in 2023 and averaged $14.3 million.
  • Examining YoY changes over the last 5 years, Jazz Pharmaceuticals' Net Cash Flow showed a top increase of 149556.64% in 2021 and a maximum decrease of 153839.29% in 2021.
  • Jazz Pharmaceuticals' Net Cash Flow (Quarter) stood at -$78.9 million in 2021, then skyrocketed by 147.11% to $37.2 million in 2022, then soared by 353.98% to $168.8 million in 2023, then increased by 16.7% to $197.0 million in 2024, then plummeted by 30.98% to $136.0 million in 2025.
  • Its last three reported values are $136.0 million in Q3 2025, -$676.7 million for Q2 2025, and -$552.6 million during Q1 2025.